The Oncology Institute Announces Addition of Board Member Mark Stolper
Rhea-AI Summary
The Oncology Institute (NASDAQ: TOI) announced that Mark Stolper joined its Board of Directors, effective January 2, 2026. Stolper currently serves as Executive Vice President and Chief Financial Officer of RadNet (NASDAQ: RDNT), a role he has held since 2004, and has prior board experience at public and private healthcare companies including 21st Century Oncology Holdings.
The company highlighted Stolper's expertise in capital markets, fundraising, strategic financial planning and payor strategy as supporting TOI's next phase of growth. Stolper commented that he expects TOI to pursue continued growth and profitability while focusing on cost-effective cancer care and improved patient outcomes.
Positive
- None.
Negative
- None.
News Market Reaction – TOI
On the day this news was published, TOI gained 6.81%, reflecting a notable positive market reaction. Argus tracked a peak move of +22.6% during that session. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $27M to the company's valuation, bringing the market cap to $421M at that time. Trading volume was elevated at 2.8x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute’s board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ: RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncology Holdings, Inc., which at the time was one of the nation’s leading radiation and medical oncology companies.
“We are very pleased to have a seasoned public company CFO like Mark join our board,” said Anne McGeorge, Chairman of the Board of The Oncology Institute. “Mark brings tremendous experience in capital markets, fundraising strategies, strategic financial planning and payor strategy that will be invaluable to TOI in our next phase of growth.”
“I am very excited to join The Oncology Institute’s Board of Directors,” commented Mr. Stolper. “The Company’s mission to provide leading-edge, cost-effective cancer care to improve outcomes and streamline the patient journey is critically important at this time in healthcare. I truly believe that TOI is poised for continued growth and profitability in the coming years.”
About The Oncology Institute
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com
Contacts
Media
The Oncology Institute, Inc.
marketing@theoncologyinstitute.com
Investors
ICR Healthcare
TOI@icrhealthcare.com
FAQ
Who joined the Board of The Oncology Institute (TOI) on January 2, 2026?
What is Mark Stolper's current role and how long has he served there?
What expertise does the new TOI board member bring for investors?
Will Mark Stolper's appointment affect TOI's growth strategy or profitability outlook?
Does Mark Stolper have prior board experience in oncology or healthcare?
